Evaluating the Evidence on Comparative Effectiveness and Value of Management Options for Treatment-Resistant Depression

被引:3
作者
Emond, Sarah K. [1 ]
Ollendorf, Daniel A. [1 ]
Colby, Jennifer A. [1 ]
Reed, Sarah Jane [1 ]
Pearson, Steven D. [1 ]
机构
[1] Inst Clin & Econ Review, Boston, MA 02109 USA
关键词
treatment-resistant depression; repetitive transcranial magnetic stimulation; evidence-based medicine; comparative effectiveness research; VAGUS NERVE-STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION;
D O I
10.3810/pgm.2013.11.2707
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Treatment-resistant depression (TRD) is a debilitating patient condition with significant clinical and economic impact. The introduction of anew treatment approach, repetitive transcranial magnetic stimulation (rTMS), created the opportunity for a multi-stakeholder initiative to examine the comparative clinical effectiveness and comparative value of the different approaches to managing patients with TRD. The New England Comparative Effectiveness Public Advisory Council (CEPAC) convened in December 2011 to discuss the evidence on management options for patients with TRD. The Council voted that rTMS was as good or better than usual care and represented a reasonable value compared with usual care. The votes and deliberation of CEPAC led to first-in-the-nation payer coverage policies allowing patients access to this new treatment option. Regional groups that examine and deliberate on the comparative effectiveness evidence for existing and emerging treatments can have a direct influence on medical policy that accelerates access to innovative treatments.
引用
收藏
页码:7 / 16
页数:10
相关论文
共 50 条
  • [41] Treatment-resistant depression: therapeutic options when first-line treatments fail
    Wigg, Chloe
    Costi, Sara
    BJPSYCH ADVANCES, 2022, 28 (01) : 4 - 8
  • [42] Treatment-resistant depression: A systematic review of systematic reviews
    Ines Perez-Wehbe, Alia
    Perestelo-Perez, Lilisbeth
    Manuel Bethencourt-Perez, Juan
    Cuellar-Pompa, Leticia
    Penate-Castro, Wenceslao
    INTERNATIONAL JOURNAL OF CLINICAL AND HEALTH PSYCHOLOGY, 2014, 14 (02) : 145 - 153
  • [43] The hidden third: improving outcome in treatment-resistant depression
    Schlaepfer, Thomas E.
    Agren, Hans
    Monteleone, Palmiero
    Gasto, Cristobal
    Pitchot, William
    Rouillon, Frederick
    Nutt, David J.
    Kasper, Siegfried
    JOURNAL OF PSYCHOPHARMACOLOGY, 2012, 26 (05) : 587 - 602
  • [44] Definition of treatment-resistant depression - Asia Pacific perspectives
    Ng, C. H.
    Kato, T.
    Han, C.
    Wang, G.
    Trivedi, M.
    Ramesh, V.
    Shao, D.
    Gala, S.
    Narayanan, S.
    Tan, W.
    Feng, Y.
    Kasper, S.
    JOURNAL OF AFFECTIVE DISORDERS, 2019, 245 : 626 - 636
  • [45] A Review of Vagus Nerve Stimulation for Treatment-Resistant Depression
    Marangell, Lauren B.
    Rush, A. John
    George, Mark S.
    Georges, Danae
    Sackeim, Harold A.
    EPILEPSY & BEHAVIOR, 2001, 2 (03) : S6 - S10
  • [46] Alternative treatments to classical antidepressants in treatment-resistant depression
    Mikellides, Georgios
    Koutsomitros, Theodoros
    Evagorou, Olympia
    Gkouvas, Nikolaos
    Su, Kuan-Pin
    Michael, Panayiota
    FRONTIERS IN PSYCHIATRY, 2023, 14
  • [47] Preclinical models of treatment-resistant depression: challenges and perspectives
    Kolasa, Magdalena
    Faron-Gorecka, Agata
    PHARMACOLOGICAL REPORTS, 2023, 75 (06) : 1326 - 1340
  • [48] Thalamocortical Dysconnectivity in Treatment-Resistant Depression
    Tu, Pei-Chi
    Lin, Wei-Chen
    Chang, Wan-Chen
    Su, Tung-Ping
    Li, Cheng-Ta
    Bai, Ya-Mei
    Tsai, Shih-Jen
    Chen, Mu-Hong
    JOURNAL OF NEUROSCIENCE RESEARCH, 2024, 102 (10)
  • [49] Barriers to Brain Stimulation Therapies for Treatment-Resistant Depression: Beyond Cost Effectiveness
    Goldbloom, David S.
    Gratzer, David
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2020, 65 (03): : 193 - 195
  • [50] FLUOXETINE EFFICACY IN TREATMENT-RESISTANT DEPRESSION
    AMSTERDAM, JD
    MAISLIN, G
    POTTER, L
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1994, 18 (02) : 243 - 261